viewAllergy Therapeutics PLC

Allergy Therapeutics pleased with the current momentum in the business

"We look forward to the exciting developments in our early pipeline planned for 2019, and we expect to continue to grow our European business while progressing towards US and German registration for our lead products," said company chairman, Peter Jensen

Woman sneezing
Those of us who suffer from hay fever enjoyed the low pollen count but it was not good news for the company

Allergy vaccines specialist Allergy Therapeutics PLC (LON:AGY) continued to gain market share in its most recent fiscal year.

The group said the year to the end of June was one of strong progress made against its strategic objectives of expanding in Europe, preparing for entry into the US market, and making clinical progress with the group's lead assets.

WATCH: Allergy Therapeutics outperforming the market "significantly" in latest financial year

Despite a low pollen season, revenue rose 6.6% to £68.3mln from £64.1mln the year before, albeit helped by currency movements; on a constant currency (CC) basis, revenue growth was 3.5%.

The group’s market share in Europe increased to 14% from 13% the previous year.

An increase in research & development costs to £16.0mln from £9.3mln the previous year led to the loss before tax widening to £6.9mln from £2.0mln the year before.

Cash at the end of June stood at £15.5mln, down from £22.1mln a year earlier, when the group raised £10.6mln through a placing of shares.

READ: Allergy Therapeutics raises £10.6mln to fund expansion of late-stage PQ Grass study

“2018 was a solid year for Allergy Therapeutics as we made important progress in key areas across the company,” said Manuel Llobet, the chief executive officer of Allergy Therapeutics.

“We generated continued growth despite a low pollen season in our core business, with constant currency revenue growth of 3.5%, driving additional gains in market share and a 26% increase in pre-R&D operating profit. We also achieved significant clinical success in the year, with the positive Phase II PQ Grass in May and we now expect headline data from the Phase III PQ Birch study by the end of the year,” he added.

“With progress towards the US market, a pipeline of exciting clinical and pre-clinical assets, and a robust balance sheet, we look to the future with confidence in our growth prospects," Llobet concluded.

In a note to clients, analysts at City broker Hardman & Co said the company was approaching profitability in 2020 according to its models, adding that sales growth was predicted to be in "mid to high single digits" over the next two years, driving market share gains.

Hardman also said they expected R&D expenditure to grow between 11% and 12% on previous years and biased toward the second half of the year due to the timing of clinical trials.

Quick facts: Allergy Therapeutics PLC

Price: 10.59 GBX

Market: AIM
Market Cap: £67.37 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Allergy Therapeutics PLC named herein, including the promotion by the Company of Allergy Therapeutics PLC in any Content on the Site, the...



Allergy Therapeutics on track for phase III grass pollen trial in 2019

Manuel Llobet, chief executive of Allergy Therapeutics plc (LON:AGY), spoke to Proactive Investors after reporting  “extremely positive results” from the phase II trial of their grass pollen-induced hay fever immunotherapy. Llobet says PQ Grass met its primary endpoint, with those...

on 21/5/18

2 min read